Previous 10 | Next 10 |
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Ann...
Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for MLD Showed Robust CNS Distribution and Expression with Improved Packaging Produc...
Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency...
Hot Penny Stocks To Buy For Under $5, Worth It? Are penny stocks worth it? That answer is something only you can come up with. But for the masses, whether you’re trading or investing in penny stocks , thousands of people hunt for the next ample opportunity to capitalize on. O...
Homology Medicines press release ( NASDAQ: FIXX ): Q3 GAAP EPS of -$0.59 misses by $0.11 . Revenue of $0.80M (-52.1% Y/Y) misses by $0.16M . As of September 30, 2022, Homology had approximately $201.1 million in cash, cash equivalents For further details ...
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving Clinical Trials and Genetic Medicines Platform Forw...
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning! Moving stocks this morning are heavy trading, earnings, stock of...
Summary The standard of care treatments for PKU have safety issues and/or limited efficacy. Recent data showed meaningful efficacy for SYNB1934 in PKU and the company will proceed to phase 3 testing. PTC Therapeutics, a competitor has a phase 3 study underway in PKU. PKU i...
SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science o...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...